FDAnews
www.fdanews.com/articles/102675-muscular-dystrophy-study-shows-promise

Muscular Dystrophy Study Shows Promise

December 31, 2007

Leiden University Medical Center (LUMC) and Dutch drugmaker Prosensa’s RNA-based therapeutic PRO051 restored dystrophin expression in patients with Duchenne Muscular Dystrophy.

The study included four patients aged 10–13 and is the first with an RNA-based therapeutic agent. The study’s results were published in The New England Journal of Medicine.

Prosensa said it is preparing for a Phase I/II study to explore the effects and safety of PRO051 after repeated systemic injections.